Siemens Fonds Invest GmbH Sells 44,507 Shares of Bristol-Myers Squibb (NYSE:BMY)

Siemens Fonds Invest GmbH decreased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 64.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 24,994 shares of the biopharmaceutical company's stock after selling 44,507 shares during the period. Siemens Fonds Invest GmbH's holdings in Bristol-Myers Squibb were worth $1,414,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of BMY. Pinney & Scofield Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $26,000. Fairway Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $28,000. Transce3nd LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $28,000. Finally, Comprehensive Financial Planning Inc. PA acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $34,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded up $0.41 on Friday, reaching $48.26. 20,756,575 shares of the stock were exchanged, compared to its average volume of 13,134,972. The stock has a market cap of $98.21 billion, a PE ratio of -10.92, a PEG ratio of 2.07 and a beta of 0.39. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The firm has a fifty day moving average price of $50.49 and a two-hundred day moving average price of $55.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($4.40) EPS. Sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.14%. Bristol-Myers Squibb's payout ratio is 92.88%.

Analysts Set New Price Targets

BMY has been the subject of a number of research reports. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Jefferies Financial Group cut their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. UBS Group cut their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Finally, Piper Sandler started coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.